Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.51 |
| ▸ | PAK4 | O96013 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 2/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379629 | 0.85 | PAK4 (0.48) | HRH3PAK4NAMPTPAK1GABRA5 | |
| SCHEMBL18325824 | 0.84 | HRH3 (0.43) | HRH3PAK4NAMPTPAK1GABRA5 | |
| SCHEMBL18325820 | 0.83 | PAK4 (0.54) | HRH3PAK4NAMPTPAK1GABRA5 | |
| SCHEMBL29611400 | 0.83 | HRH3 (0.42) | HRH3PAK4NAMPTPAK1GABRA5 | |
| SCHEMBL16346356 | 0.83 | HRH3 (0.42) | HRH3PAK4NAMPTPAK1GABRA5 | |
| SCHEMBL16379573 | 0.83 | PAK4 (0.42) | HRH3PAK4NAMPTGABRA5LOXL2 | |
| SCHEMBL16379761 | 0.82 | PAK4 (0.69) | HRH3PAK4NAMPTPAK1GABRA5 | |
| SCHEMBL29611290 | 0.81 | PAK4 (0.52) | HRH3PAK4NAMPTPAK1GABRA5 | |
| SCHEMBL16379559 | 0.81 | PAK4 (0.52) | HRH3PAK4NAMPTPAK1GABRA5 | |
| SCHEMBL16345227 | 0.81 | PAK4 (0.51) | HRH3PAK4NAMPTPAK1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | disclosed |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-9856241-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | HRH3 4677/4885PAK4 2007/4885NAMPT 1663/4885 |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | HRH3 4681/4885PAK4 2260/4885NAMPT 1782/4885 |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | HRH3 4681/4885PAK4 2260/4885NAMPT 1782/4885 |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | HRH3 4681/4885PAK4 2260/4885NAMPT 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.